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Cadaverine, a metabolite of the 
microbiome, reduces breast cancer 
aggressiveness through trace 
amino acid receptors
tünde Kovács1, edit Mikó1,5, András Vida1,5, Éva Sebő6, Judit toth3, tamás Csonka4, 
Anita Boratkó1, Gyula Ujlaki1, Gréta Lente1, patrik Kovács1, Dezső tóth3, péter Árkosy3, 
Borbála Kiss2, Gábor Méhes4, James J. Goedert7 & péter Bai1,5,8
Recent studies showed that changes to the gut microbiome alters the microbiome-derived metabolome, 
potentially promoting carcinogenesis in organs that are distal to the gut. In this study, we assessed the 
relationship between breast cancer and cadaverine biosynthesis. Cadaverine treatment of Balb/c female 
mice (500 nmol/kg p.o. q.d.) grafted with 4T1 breast cancer cells ameliorated the disease (lower mass and 
infiltration of the primary tumor, fewer metastases, and lower grade tumors). Cadaverine treatment of 
breast cancer cell lines corresponding to its serum reference range (100–800 nM) reverted endothelial-
to-mesenchymal transition, inhibited cellular movement and invasion, moreover, rendered cells less 
stem cell-like through reducing mitochondrial oxidation. Trace amino acid receptors (TAARs), namely, 
TAAR1, TAAR8 and TAAR9 were instrumental in provoking the cadaverine-evoked effects. Early stage 
breast cancer patients, versus control women, had reduced abundance of the CadA and LdcC genes 
in fecal DNA, both responsible for bacterial cadaverine production. Moreover, we found low protein 
expression of E. coli LdcC in the feces of stage 1 breast cancer patients. In addition, higher expression of 
lysine decarboxylase resulted in a prolonged survival among early-stage breast cancer patients. taken 
together, cadaverine production seems to be a regulator of early breast cancer.
Microbes that live on the surface or the cavities of the human body affect a large set of pathophysiological pro-
cesses ranging from metabolic diseases to psychiatric disorders1–4 or neoplastic dieases3,5–7. The number of 
directly tumorigenic bacteria is extremely low (~10 species)8, however, dysbiosis is associated with cancers of the 
urinary tract9, cervix10, skin11, airways12, the colon8, lymphomas13,14, prostate9 and breast cancer15–22. Dysbiosis 
is often reflected as a loss of diversity of the microbiota (e.g.16). In colon carcinogenesis, immunogenic microbes 
probably promote the malignancy. However, the majority of the aforementioned cancers are located distantly 
from larger depots of microbes, hence, suggesting indirect induction or promotion mechanisms. Indeed, bacterial 
metabolites emerge as “endocrine” agents that are produced by the microbiome, are absorbed into the circulation, 
and exert their biological effects distantly.
Deconjugated estrogens17,18, secondary bile acids23–28, lipopolysaccharide29 or propionate (a short chain 
fatty acid (SCFA))30 were proposed to be involved in regulating transformation or cancer cell proliferation. 
Nonetheless, the molecular mechanisms, through which bacterial metabolites expert their effects are largely 
unknown. Deoxycholic acid (DCA) was shown to reprogram the hepatocyte secretome, thereby, promoting hepa-
tocellular carcinoma23,24. Another secondary bile acid, lithocholic acid was shown to inhibit proliferation of breast 
cancer cells through inhibiting Warburg metabolism and endothelial-to-mesenchymal transition, as well as by 
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enhancing antitumor immunity26. LCA exerted its antitumor effects through the TGR5 receptor26. Importantly, 
the latter study showed that in early stages of breast cancer bacterial LCA biosynthesis was decreased suggesting 
a loss of an antiproliferative bacterial metabolite26.
Cadaverine (CAD) is produced by the decarboxylation of lysine that is performed by lysine decarboxylase 
(LDC) enzymes. Human cells code and express LDC, but numerous bacterial species of the human microbiome 
also expresses LDC either in a constant (LdcC in the LDC operon) or in an inducible (CadA in the Cad operon) 
fashion31,32. Bacteria use diamines, like cadaverine or putrescine, generated by the decarboxylation of lysine or 
arginine, to buffer the pH of their environment27. The effects of cadaverine on cancer cells and its role in car-
cinogenesis is not characterized in detail. Therefore, we wanted to assess whether cadaverine can influence the 
behavior of breast cancer cells.
Results
Cadaverine treatment reduces metastasis formation in 4T1-grafted mice. As first step, we tested 
the effects of cadaverine supplementation (500 nmol/kg) to mice homotopically grafted with 4T1 breast cancer 
cells. Cadaverine supplementation did not alter the number of primary tumors that grew from the grafted cells 
(Fig. 1A), but there was a trend towards tumors with lower mass (Fig. 1B). In line with that, the number of metas-
tases decreased (Fig. 1C) and, as with the primary tumors, there was a trend for smaller metastases in the cadav-
erine-treated mice (Fig. 1D). Importantly, cadaverine treatment decreased the invasivity of the primary tumors 
(Fig. 1E). Histological examination of the primary tumors revealed that cadaverine treatment decreased the rate 
of mitosis (Fig. 1F,G), the heterogeneity of nuclear morphology (Fig. 1H).
Cadaverine administration does not impair breast cancer proliferation. We investigated whether 
cadaverine administration could influence the proliferation of cultured breast cancer cell lines. We used five 
different established breast cancer cell lines of which four were of human (MD-MBA-231, SKBR3, ZR-75-1 and 
MCF7), while one was of murine origin (4T1). The cadaverine concentration that we used corresponded to the 
reference concentration of cadaverine in human serum (100–800 nM)33,34. Cadaverine slowed proliferation of 
4T1, MDA-MB-231 and SKBR-3 cells as measured in SRB assay (Fig. 2A) or in colony forming assays (Fig. 2B), 
although the changes were not statistically significant. Importantly, the same concentrations of cadaverine did 
not hinder the proliferation of non-transformed primary human skin fibroblasts (Fig. 2A). We assessed whether 
slower proliferation could be due to the toxicity of cadaverine to cells. The proportion of the PI positive cells did 
not increase upon cadaverine treatment (Fig. 2D), nor did the apoptotic fraction in 4T1 cells (Fig. 2C).
Cadaverine induced a mesenchymal-to-epithelial (MET) transition and invasion. We assessed 
whether cadaverine treatment can revert mesenchymal-like cancer cells to epithelial-like cells. First, we 
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Figure 1. Cadaverine treatment reduces breast cancer aggressiveness in vivo. Female Balb/c mice were grafted 
with 4T1 cells as described and were treated with cadaverine (500 nmol/kg q.d. p.o.; CAD group) or vehicle 
(CTL) (n = 16/16) for 16 days before sacrifice. 6 samples from CTL group and 8 samples from cadaverine group 
underwent histological analysis. In CTL and CAD group (A) the number and (B) mass of primary tumors 
were counted and the (C) number and (D) mass of metastases were measured upon autopsy. (E) Upon autopsy, 
the infiltration rate of the primary tumor was scored. Significance (p = 0.002) was calculated using Fisher’s 
exact test with 2 × 3 Contingency Table. (F–H) Primary tumors were formalin-fixed and were embedded 
into paraffin, then sections were hematoxylin-eosin stained and were scored for (F) mitosis (p = 0.0031), (G) 
mitosis/hpf (p = 0.027) and (H) nuclear pleomorphism (p = 0.0097). Data is plotted as mean ± SEM. In box-
whiskers charts (panels B and D) middle lines indicate the median, while red square symbol the mean. * and ** 
indicate statistically significant difference between CTL and CAD groups at p < 0.05 or p < 0.01, respectively. 
Significance was calculated using two-sample student t-test (two-tailed) except for panel E, F and H, where Chi-
square or Fisher’s exact test was used.
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performed a measurement in the ECIS system in which 0.1 µM cadaverine increased resistance, suggesting bet-
ter adherence of cells (Fig. 3A). To verify these findings, we stained cells with Phalloidin-Texas Red to visualize 
the arrangement of the actin cytoskeleton. Cadaverine treatment changed the fibroblast-like morphology of the 
4T1 cells to a rather cobblestone-like morphology (Fig. 3B) that is characteristic for epithelial cells26. Treatment 
of MDA-MB-231 and SKBR-3 breast cancer cell lines with cadaverine led to similar morphological changes 
(Fig. S1A,D).
To gain insight into the molecular mechanism through which MET takes place we performed an RT-qPCR 
screen on EMT genes. The assay revealed differential expression of 11 genes after cadaverine treatment (Table 1), 
most were suppressed. MMP2, MMP3 and MMP9 support movement; Tgfb3, FgFbp1, Erbb3 and Er1 support 
proliferation; while Krt14, Notch1, CDH1, IgFbp4 and Spp1 support cell adhesion (Fig. 3C–E).
In line with these observations, cadaverine-treated cells were slower in migrating to open areas in scratch 
assays (Fig. 4A) and also performed worse in Boyden-chamber transmigration tests (Fig. 4B). These data were 
further supported by the observation that MMP9 expression was suppressed by cadaverine treatment in 4T1 cells 
(Fig. 4C), as well as in MDA-MB-231 and SKBR-3 breast cancer cell lines (Fig. S1B,E). We assessed metabolic 
changes evoked by cadaverine administration using the Seahorse flux analyzer. Cadaverine treatment reduced gly-
colytic flux (Fig. 4D) that is a characteristic of breast cancer stromal cells35. Therefore, we assessed the “stem-ness” 
of 4T1 cells using the aldefluor assay and found a mild reduction in cancer cell stem-ness (Fig. 4E). We found 
similar reductions in cancer cell stem-ness in MDA-MB-231 cells upon cadaverine treatment (Fig. S1C). We did 
not detect changes in lipid oxidation (Fig. S2).
Cadaverine exert its beneficial effects through Trace Amino Acid Receptors (TAARs). The trace 
amino acid receptor family serve as receptors for cadaverine36. Although, most studies on TAAR focused on 
olfaction36, a study linked TAAR1 to breast cancer37. Indeed, higher expression of TAAR1, TAAR2, TAAR4, 
TAAR5, TAAR8 (in ER- cases) and TAAR9 provided better survival in breast cancer (Fig. 5A, Table 2). First, as 
TAAR receptors are G protein-dependent receptors36 we assessed their involvement by treating 4T1 cells with 
NF449, a Gsα-subunit-selective G-protein antagonist, a treatment that abolished the anti-EMT effect of cadav-
erine (Fig. 5B). Next, we silenced TAAR1, TAAR8 and TAAR9 in MDA-MB-231 cells (Fig. 5C). The silencing 
of TAAR1, TAAR8 and TAAR9 prevented the cadaverine-elicited mesenchymal-to-epithelial transition and the 
silencing of TAAR8 and TAAR9 prevented the cadaverine-induced decrease in MMP9 expression (Fig. 5D,E).
Figure 2. Cadaverine reduces the proliferation and colony forming ability of breast cancer cells. (A) 4T1 
(n = 6 in octuplicates), MDA-MB-231 (n = 3 in octuplicates), SKBR-3 (n = 3 in octuplicates), ZR-75-1 (n = 3 
in octuplicates) and MCF-7 (n = 3 in octuplicates) breast cancer cells and primary fibroblasts cells were treated 
with cadaverine in the concentrations indicated for 48 hours then total protein concentrations were determined 
in SRB assay. Values are expressed as fold change, where 1 means protein content in the control cells (indicated 
by a dotted line). (B) 4T1, MDA-MB-231, SKBR-3, ZR-75-1 and MCF-7 (n = 3 for each in one replicate) cells 
were treated with cadaverine in the concentrations indicated for 4 days. Colonies were then stained according 
to May-Grünwald-Giemsa and counted using Image J software (n = 3). (C) 4T1 cells (n = 3 in triplicates) 
were treated with cadaverine in the concentrations indicated for 48 hours. Cells were stained with Annexin-
FITC-PI Apoptosis Kit and analyzed by flow cytometry (n = 4). (D) 4T1 (n = 3 in triplicates), MDA-MB-231 
(n = 4 in triplicates), SKBR-3 (n = 4 in triplicates), ZR-75-1 (n = 3 in triplicates), MCF-7 (n = 3 in triplicates) 
and primary fibroblasts cells were treated with cadaverine in the concentrations indicated for 48 hours. Dead 
cells were stained with propidium iodide (PI) and analyzed by flow cytometry. Data is plotted as mean ± SEM. 
Significance was calculated using one-way ANOVA test. CAD – cadaverine, other abbreviations are in the text. 
Double-headed arrow mark the serum reference concentration of cadaverine on panel A.
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We assessed the available databases to collect data on TAAR1, TAAR8 and TAAR9. TAAR1 and TAAR9 
expression did not show any major association with carcinogenesis or breast cancer subtypes in contrast to 
TAAR8. TAAR8 expression decreased in pre-cancerous lesions, such as hyperplastic enlarged lobular units 
(HELUs) as compared to normal terminal ductal lobular units (TDLUs)38. In line with that, TAAR8 expression 
decreased in breast cancer39. Decreases in TAAR8 expression was different between the histological subtypes 
of breast cancer. TAAR8 expression was lower in triple negative breast cancers as compared to non-triple neg-
ative breast cancers. There was a trend for lower TAAR8 expression in DCIS when compared to healthy tis-
sue40, TAAR8 expression was lower in ductal invasive breast cancer as compared to healthy ducts41 and there 
was a trend for lower TAAR8 expression in lobular invasive breast cancer as compared to healthy lobes41. Taken 
together, apparently, in early stage of breast cancer TAAR8 expression decreases that is more pronounced in triple 
negative breast cancers.
Cadaverine biosynthesis is suppressed in breast cancer. To get an insight whether intestinal cadaver-
ine biosynthesis is modified in breast cancer patients, we assessed the abundance of the DNA coding for LdcC and 
CadA in human fecal DNA from the experimental cohort described in16. We designed primers for known CadA 
and LdcC genes in different bacteria. When comparing healthy individuals and breast cancer patients we observed 
slightly decreased abundance of Escherichia coli CadA and also E. coli, Enterobacter cloacae and Hafnia alvei LdcC 
DNA in breast cancer patients (Fig. 6A). Decreased CadA and LdcC abundance was more pronounced in clinical 
stage 0 patients as compared to the pool of all patients (Fig. 6A). Subsequently, we assessed the protein levels of E. 
coli LdcC protein in feces by Western blotting. In the feces of stage 1 patients LdcC protein levels were markedly 
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Figure 3. Cadaverine treatment reverses EMT of breast cancer cells. (A,B) In control and cadaverine-treated 
4T1 cells (A) total cellular impedance was measured by ECIS (n = 2 in duplicate) (p = 0.0484 at 36 hrs. and 
0.0487 at 40 hrs.) and (B) morphology of the actin cytoskeleton (representative picture of control and 0.1 µM 
cadaverine-treated cells) was assessed after Texas Red-X Phalloidin + To-Pro-3 staining (n = 2 in triplicates), 
ratio (%) of epithelial and mesenchymal cells was shown on bar chart. Significance was calculated using Chi-
square test in Microsoft Excel (p = 2.97 × 10−28 between control and 0.1 µM cadaverine, p = 1.04 × 10−18 
between control and 0.3 µM cadaverine, p = 3.97 × 10−10 between control and 0.8 µM cadaverine). (C–E) 
Expression of a set of genes involved in EMT were assessed by RT-qPCR in (C) 4T1 cells (n = 3), (D) primary 
tumors (n = 16/16) and in (E) metastases (n = 16/16). All data is expressed as fold change. The red line that 
equals to 1 (no change) indicate the average of the control samples. Data is plotted as mean ± SEM. On panel 
A and C-E significance was calculated using two-sample student t-test (two-tailed), while on panel B One-
way Anova was used to calculate differences. Significant p values were shown in Supplementary Table 4. *,** 
and *** indicate statistically significant difference between control and treated groups at p < 0.05, p < 0.01 or 
p < 0.001 respectively. CAD – cadaverine, other abbreviations are in the text.
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We assessed the GEO database to study LDC expression in human breast cancer. There was no difference in 
LDC mRNA expression between control and breast cancer cases42–44 or in LDC expression of the normal breast 
epithelium and cancer epithelium in patients45. Rather as an exception, LDC expression was lower in basal-like 
breast cancer as compared to control (normal) breast epithelium of non-diseased individuals46.
Finally, we assessed how expression of LDC in humans affects the outcome of breast cancer using the kmplot.
com database (the acquired data is represented in Table 3). Although, differences in LDC expression did affect 
Figure 4. Cadaverine treatment attenuate movement, invasion ability, mitochondrial oxidation and stem-
ness of 4T1 cells. (A) 4T1 cells were treated with cadaverine in the concentrations indicated for 48 hours after 
scratching a 4T1 cell layer. Subsequent closure of the wound was assessed by the JULI-Br live cell analyzer 
system (n = 2). Significance was calculated using two-sample student t-test (two-tailed). (B) 4T1 cells were 
treated with cadaverine for 48 hours and subsequently invasion capacity of the cells was measured using the 
Corning Matrigel invasion chamber. Cells were counted using the Opera HCS system and invasion index 
was calculated (p = 0.003 both between control and 0.1 µM cadaverine, and control and 0.3 µM cadaverine, 
p = 4.14 × 10−4 between control and 0.8 µM cadaverine). (C) 4T1 cells were treated with vehicle and 
cadaverine for 48 hours, then cells were stained for MMP9 and nucleus (DAPI) and sections were analyzed by 
confocal microscopy using a Leica SP8 confocal system. MMP9 content was calculated from the total cellular 
fluorescence measured by the Image J software (p = 0.001 between both control and 0.3 µM cadaverine and 
control and 0.8 µM cadaverine). (D) 4T1 cells were treated with vehicle and cadaverine for 48 hours (n = 3 in 
24 replicates), then cells were subjected to a Seahorse XF96 analysis. Oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) were measured and plotted (pOCR = 0.006 between control and 0.1 µM 
cadaverine, pOCR = 1.14 × 10−6 between control and 0.3 µM cadaverine, pOCR = 1.8 × 10−5 between control and 
0.8 µM cadaverine). (E) 4T1 cells were treated with vehicle and cadaverine for 48 hours (n = 3 in triplicates), 
then cells were subjected to an Aldefluor assay (p = 0.035 between control and 0.3 µM cadaverine). Data is 
plotted as mean ± SEM. Significance was calculated using One-way Anova. *,** and *** indicate statistically 
significant difference between control and treated groups at p < 0.05, p < 0.01 or p < 0.001 respectively. CAD – 
cadaverine, other abbreviations are in the text.
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overall survival of the patients, in grade 1 patients higher expression of LDC was associated with significantly 
longer survival than lower expression of LDC (Fig. 6C). Interestingly, while LDC expression did not affect sur-
vival in ER- PR- patients, higher LDC expression correlated with better survival in ER+ PR+ patients (Fig. 6D).
Discussion
In this study we assessed how cadaverine affects the behavior of breast cancer cells. Cadaverine is an ill-characterized 
biogenic amine as compared to – for example – putrescine that is characterized as a pro-carcinogenic agent31,47. 
Increased levels of diamines are in positive correlation with carcinogenesis; serum level of diamines are higher in 
cancer patients than in healthy individuals33,34,48. Moreover, surgical removal of tumors normalize serum diamine 
levels33,34. Based on these observations, polyamines were suggested as cancer markers49, although their efficiency was 
not proven47. While in the available literature levels of putrescine were equivocally higher in various cancer patients 
than in healthy individuals33,34,48, cadaverine levels were more variable among the studies, some reporting increases 
in cadaverine levels33,34,48, others with trends for decreases50. Breast cancer patients have not been evaluated.
Our data suggests that cadaverine has a tumor suppressor role in breast cancer in concentrations correspond-
ing to the human reference range33,34. Cadaverine exerted its effects through inhibiting EMT, cellular movement, 
chemotaxis and metastasis (Fig. 7). These concentrations are much lower than the ones used in previous in vitro 
studies (10 µM in51 or 100 µM in52). Moreover, similarly to another cytostatic bacterial metabolite, lithocholic 
acid26, cadaverine, in the concentrations corresponding to its reference concentration, did not exert its cytostatic 
effects on primary fibroblasts suggesting that its effects are specific for tumor cells.
Figure 5. TAARs are important in mediating the effects of cadaverine. (A) Patient data was accessed at kmplot.
com. Kaplan-Meier plots show the correlation between the mRNA expression of human TAARs and survival in 
breast cancer. (B) 4T1 cells were treated with, 100 nM cadaverine (48 hours) or 100 nM cadaverine (48 hours) 
in combination with 5 µM NF449 G protein inhibitor (last 48 hours of cadaverine treatment), cells were stained 
with Texas Red-X Phalloidin- and DAPI then cells were assessed by confocal microscopy (n = 2 in triplicates). 
(C) MDA-MB-231 cells were transfected with control si RNA or TAAR si RNA. The silencing efficacy was 
measured by Western blot (n = 2). (D,E) MDA-MB-231 cells were treated with vehicle or 0.3 μM cadaverine 
and transfected with control si RNA or TAAR si RNA. After 48 hours of incubation (D) TexasRed-X Phalloidin 
immunocytochemistry (p = 0.04 between cadaverine and TAAR1, p = 0.007 between cadaverine and TAAR8, 
p = 0.003 between cadaverine and TAAR9) (n = 1 in triplicates), and (E) MMP9 immunocytochemistry 
(p = 0.006 between control and TAAR1; p = 0.001 between cadaverine and TAAR8; p = 0.004 between 
cadaverine and TAAR9) (n = 1 in triplicates) were performed. CAD – cadaverine, other abbreviations are in the 
text.
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Cadaverine was shown to activate TAARs, moreover, a study linked TAAR1 to breast cancer37. Our results 
pointed out the possible involvement of TAAR1, TAAR2, TAAR3, TAAR5, TAAR8 and TAAR9 in bringing about 
the anticancer effects of cadaverine. High expression of these receptors in tumors associated with better survival. 
TAAR1 (1553930_at) HR (Hazard Ratio) P-value (Log Rank Test)
All Breast Cancers, N = 1764 0.8 6.1 × 10−3
ER(−), N = 516 0.77 0.054
ER(+), N = 1248 0.83 0.052
Basal subtype, N = 360 0.66 0.011
Luminal B, N = 407 0.67 0.01
TAAR2 (221394_at)
All Breast Cancers, N = 3951 0.73 1.90 × 10−8
ER(−), N = 869 0.65 6.20 × 10−5
ER(+), N = 2061 1.07 0.4
Basal subtype, N = 618 0.66 1 × 10−3
Luminal B, N = 1149 0.66 3.10 × 10−5
TAAR3 (221393_at)
All Breast Cancers, N = 3951 0.8 6.30 × 10−5
ER(−), N = 869 0.69 4.5 × 10−4
ER(+), N = 3082 0.86 0.018
Basal subtype, N = 618 0.76 0.036
Luminal B, N = 1149 0.67 4.20 × 10−5
TAAR5 (221459_at)
All Breast Cancers, N = 3951 0.76 7.80 × 10−7
ER(−), N = 869 0.75 8.3 × 10−3
ER(+), N = 3082 0.8 6.00 × 10−4
Basal subtype, N = 618 0.73 0.016
Luminal B, N = 1149 0.62 1.00 × 10−−6
TAAR8 (1553552_at)
All Breast Cancers, N = 1764 0.94 0.42
ER(−), N = 516 0.69 5.8 × 10−3
ER(+), N = 1248 1.1 0.31
Basal subtype, N = 360 0.64 7.8 × 10−3
Luminal B, N = 407 0.97 0.85
TAAR9 (1553066_at)
All Breast Cancers, N = 1764 0.58 8.10 × 10−12
ER(−), N = 516 0.55 1.40 × 10−5
ER(+), N = 1248 0.6 2.30 × 10−7
Basal subtype, N = 360 0.5 4.80 × 10−5
Luminal B, N = 407 0.69 0.017
Table 2. Connection between TAARs and Breast Cancer Patient survival.
Abbreviation Gene name Category
MMP2 Matrix Metalloproteinase 2
Extracellular matrix 
and cell adhesion
MMP3 Matrix Metalloproteinase 3
MMP9 Matrix Metalloproteinase 9
Krt14 Keratin 14
CDH1 E-cadherin
Spp1 Secreted Phosphoprotein 1
FgfBp1 Fibroblast Growth Factor Binding Protein 1
Cell growth and 
proliferation
Notch1 Notch 1
Tgfb3 Transforming Growth Factor Beta 3
Erbb3 Human Epidermal Growth Factor Receptor 3
Esr1 Estrogen Receptor 1
IgfBp4 Insulin Like Growth Factor Binding Protein 4
Table 1. List of EMT genes differentially regulated upon cadaverine treatment.
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The lack of commercially available reagents limited us in validating these findings, we were able to test TAAR1, 
TAAR8 and TAAR9. All receptors were involved in regulating the mesenchymal-to-epithelial transition, however, 
only TAAR8 and TAAR9 modulated MMP9 expression (Fig. 7). Furthermore, the expression of TAAR8 was 
reduced in precancerous states and was gradually downregulated as the severity of the disease worsened; we have 
not found such correlations with TAAR1 or TAAR9. Available metadata suggest that TAAR8 has strong inverse 
correlation with breast cancer severity. Due to the limited availability of reagents, we cannot exclude that other 
TAARs could be equally involved in regulating cadaverine-evoked effects besides the ones we identified.
Our data suggest that bacterial cadaverine biosynthesis decreases in the gut in early stage breast cancer, result-
ing in lower production of an anti-cancer bacterial metabolite. In that sense, lower cadaverine production is in 
line with the lower production of another cytostatic microbial metabolite, lithocholic acid26. On a broader scale, 
these observations suggest that the simplification of the gut microbiome in early stage breast cancer16,26 leads 
to a decreased production of antiproliferative bacterial metabolites like cadaverine or lithocholic acid26. This 
observation is further supported by the observation that there is a positive correlation between breast cancer 
incidences or recurrence and cumulative antibiotic use53–58. Antibiotic exposure increased breast cancer risk in a 
dose-dependent fashion, nevertheless, these are correlative studies, and the chance of uncontrolled confounding 
is high and certain studies have found no association53,54,56–58. Apparently, the cumulative antibiotic dose is in 
correlation with increases in breast cancer frequency regardless of antibiotic class, although, the strongest effects 
were associated with the intermitting use of tetracyclins and macrolids55.
Figure 6. Cadaverine biosynthesis is suppressed in early stages of breast cancer. (A) Human fecal DNA 
samples were collected from 48 patients with different stages of breast cancer, and from 48 healthy patients. The 
abundance of DNA coding for CadA and LdcC of the indicated bacterial species were determined in the fecal 
DNA samples by RT-qPCR. Median values are indicated by a line. (B) Human fecal samples were collected from 
stage 1 breast cancer patients (n = 7) and from healthy (control) subjects (n = 3). The E. coli LdcC protein level 
was determined using Western blot. Hereby we show a representative image. Band intensity was normalized to 
total protein content assessed by ponceau-S staining of whole blots. Box chart of LDC protein expression from 
fecal samples (p = 0.003). Data was normalized to the mean of control samples. Blots were routinely cut as the 
representative blot. (C,D) Patient data was accessed at kmplot.com. Kaplan-Meier plots the correlation between 
the mRNA expression of human LDC and survival in breast cancer. Graphs show the correlation between LDC 
and disease survival in different forms and stages of the disease. Those arrays were also included where ER 
status was deducted from gene expression data. **Indicate statistically significant difference between control 
and treated groups at p < 0.01. Significance was calculated using two-sample student t-test (two-tailed). All 
abbreviations are in the text. Values on (A) were log2 transformed.
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The most drastic changes to the microbiome was associated with in situ carcinoma or stage I carcinoma, 
in later stages cadaverine production re-increased and reached levels similar to the level of the controls. These 
findings are similar to our previous observations, in breast cancer the abundance of the cadaverine-producing 
bacteria was the lowest in in situ carcinoma and stage I carcinoma patients26. Nevertheless, the in silico data that 
we gathered for TAAR8 suggest that in parallel to the simplification or dysbiosys of the microbiome in tumors the 
expression of the cadaverine-sensing apparatus is probably downregulated.
There are other sources of cadaverine. Milk ducts in the breast are colonized by bacteria and the duct microbi-
ome changes upon breast cancer19–22 that may contribute to changes in the breast pool of cadaverine. In addition 




P-value (Log Rank 
Test)
All Breast Cancers, N = 3951 1.07 0.23
ER(+), PR(+), N = 577 0.69 0.045
ER(+), PR(+), Lymph node(+), N = 344 0.52 3.4 × 10−3
ER(+), PR(+), Lymph node(−), N = 228 0.76 0.39
ER(−), PR(−), N = 298 0.94 0.74
ER(−), PR(−), Lymph node(+), N = 127 0.76 0.32
ER(−), PR(−), Lymph node(−), N = 167 0.89 0.69
ER(−), PR(−), HER2(−), N = 198 1.01 0.98
ER(+), Luminal A, N = 1933 1.15 0.1
ER(+), Luminal A, Grade 1, N = 267 0.45 0.014
ER(+), Luminal B, N = 1149 1.11 0.27
ER(+), Luminal B, Grade 1, N = 56 1.73 0.39
Grade 1, N = 345 0.6 0.055
Grade 2, N = 901 0.83 0.13
Grade 3, N = 903 1.06 0.59
Basal subtype, N = 618 1.18 0.19
Luminal A, N = 1933 1.15 0.1
Luminal B, N = 1149 1.11 0.27
ER(+), HER2(+), N = 156 0.96 0.9
ER(−), HER2(+), N = 96 1.57 0.16
Table 3. Breast cancer survival and Lysine decarboxylase.
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to these, human cells also synthesize cadaverine. High expression of human LDC prolongs survival in early stage 
breast cancer patients, further supporting the potential anti-cancer properties of cadaverine. Nevertheless, the 
share of these sources (healthy breast tissues vs. tumor vs. host vs. gut) in cadaverine production is not explored.
This study puts cadaverine on the list of bacterial metabolites that govern carcinogenesis. Lithocholic acid26 
and cadaverine can suppress cancer hallmarks of breast cancer cells. In hepatocellular carcinoma, lipopolysaccha-
ride29 and deoxycholic acid (DCA)23 have been identified as promoters, while propionate is an inhibitor30. These 
observations support the hypothesis that bacterial metabolites influence carcinogenesis in organs remote from 
the gut. Nevertheless, this field requires considerably more research to understand the interactions between the 
microbiome and distantly located tumors.
Methods
All methods were performed according to the relevant guidelines.
Chemicals. Chemicals, among them, cadaverine were from Sigma-Aldrich (St. Louis, MI, USA) unless oth-
erwise stated.
Cell culture. 4T1 murine breast cancer cells, ZR-75-1 human breast cancer cells were maintained in RPMI-
1640 (Sigma-Aldrich, R5886) medium containing 10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine and 
1% pyruvate at 37 °C with 5% CO2.
MDA-MB-231 and SK-BR-3 human breast cancer cells were maintained in DMEM (Sigma-Aldrich, 1000 mg/l 
glucose, D5546) containing 10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine and 10 mM HEPES at 37 °C 
with 5% CO2.
MCF7 human breast cancer cells were maintained in MEM (Sigma-Aldrich, M8042) medium containing 10% 
FBS, 1% penicillin/streptomycin, 2 mM L-glutamine and 10 mM HEPES at 37 °C with 5% CO2.
Human primary fibroblast cells were maintained in DMEM (Sigma-Aldrich, 1000 mg/l glucose, D5546) con-
taining 20% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine and 10 mM HEPES at 37 °C with 5% CO2.
transfections. Transfections were performed as in59.
Cell proliferation assays. Sulphorhodamine B assay and colony forming assays were performed as in26,60.
Detection of cell death. For the detection of cell death we used simple propidium iodide (PI, Biotium, 
Fremont, CA, 40016) uptake assays (as in61), while to differentiate between apoptosis and necrosis we used an 
Annexin V + PI double staining assay kit (Invitrogen, Oregon, USA, V13242).
Electric Cell-substrate Impedance Sensing (ECIS). ECIS assays were performed similarly to26. ECIS 
measurements are used to assess cell-to-cell and cell-to-surface connections.
Immunocytochemistry. Immunocytochemistry was performed similarly to26,62.
Bacterial LdcC and CadA quantitation. The human fecal DNA library from breast cancer patients was 
published in16. For the determination of the abundance of Lysine decarboxylase coding DNA in human fecal 
DNA samples 10 ng of DNA was used for qPCR reactions. Primers are listed in Supplementary Table 1. The ampli-
cons were subsequently sequenced using the same primers as listed in Supplementary Table 1.
mRNA isolation and quantitation. Reverse transcription-coupled PCR (RT-qPCR) was performed sim-
ilarly to63.
Fecal protein sample preparation. RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 
0.5% sodium deoxycholate, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, protease inhibitor cocktail) 
was used to lyse cells of fecal samples. Samples were sonicated (Qsonica Q125 Sonicator, Newtown, Connecticut) 
3 times for 30 seconds with 50% amplitude. After centrifugation, 25 µl 5 X SDS sample buffer (50% glycerol, 10% 
SDS, 310 mM Tris HCl, pH 6.8, 100 mM DTT, and 0.01% bromophenol blue) and 8 µl β-mercaptoethanol were 
added to every 100 µl supernatant. Samples were heated 10 minutes at 96 °C and kept on ice until loading.
sDs-pAGe and Western blotting. SDS PAGE and Western blotting was performed as in63.
scratch assay. Scratch assays were performed as in26. Scratch assays were employed to assess cell movement.
Invasion. Matrigel invasion assay was carried out on 4T1 cells using Corning BioCoat Matrigel Invasion 
Chamber (354480). 4T1 cells were seeded in the chambers (50000 cells/well) in serum free medium, and were 
grown overnight. Cells were then treated with different concentration of cadaverine (0.1 µM, 0.3 µM, 0.8 µM). 
The lower chamber contained full 4T1 medium with 100 ng/ml SDF1-alpha (Sigma, SRP4388) as chemoattract-
ant. After 48 hours of cadaverine treatment cells were prepared according to the manufacturer’s instructions 
and stained with Hematoxylin-Eosin (VWR, 340374T and 341972Q) dye. Cells were then pictured with Opera 
Phoenix High Content Screening System and pictures were analyzed using Harmony 4.6 Software. Invasion index 
was calculated from the percentage of invading cells through Matrigel membrane and control membrane.
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= ∗Invasion Mean of cells invading through Matrigel insert membrane
Mean of cells invading through Control insert membrane
% 100




Seahorse metabolic flux analysis. Changes to oxygen consumption rate (OCR, a readout of mitochon-
drial oxidation) and in pH (ECAR, a readout of lactate production and glycolytic flux) after cadaverine treatment 
were performed similarly to26.
Determination of lipid peroxidation (TBARS). TBARS assay was performed to assess lipid peroxidation 
as in64.
Aldefluor assay. Aldefluor assay for assessing stem-ness was performed similarly to65.
Animal study. Animal studies were conducted similarly to26.
Animal experiments were approved by the Institutional Animal Care and Use Committee at the University of 
Debrecen and the National Board for Animal Experimentation (1/2015/DEMÁB) and were carried out according 
to the NIH guidelines (Guide for the care and use of laboratory animals) and applicable national laws. Animal 
studies are reported in compliance with the ARRIVE guidelines66,67.
We used BALB/c female mice (4 months of age, 20–25 g). Animals were bred in the “specific pathogen free” 
zone of the Animal Facility at the University of Debrecen, and kept in the “minimal disease” zone during the 
experiments. 4 mice were housed in one cage (standard block shape 365 × 207 × 140 mm, surface 530 cm2; 1284 L 
Eurostandard Type II. L from Techniplast). Dark/light cycle was 12 h, and temperature was 22 ± 1 °C. Mice had 
ad libitum access to food and water (sterilized tap water). A total of 32 female mice were used in the study, 16 
randomly selected control and 16 cadaverine fed mice. The study was performed in two runs at two different 
occasions, each run comprising of 8 vehicle-treated and 8 cadaverine-treated mice.
Tumor was formed in mice by the grafting of 4T1 cells. 4T1 cells were suspended (2 × 106/mL) in ice cold 
PBS-Matrigel (1:1, Sigma-Aldrich). 16 female BALB/c mice received 50 µL injections to the inguinal fat pads 
below the lower abdominal nipples on both sides (105 cells/injection site).
Animals received daily oral cadaverine treatment. Cadaverine stock was prepared in sterilized tap water at 
100x concentration (15 mM) and the stock was stored at −20 °C. Cadaverine stock was diluted each day to a 
working concentration of 150 µM in sterile tap water before the treatment. Animals received a daily oral dose of 
100 µl/30 g bodyweight from cadaverine solution (8 mice) or vehicle (sterilized tap water, 8 mice). Researchers 
administering cadaverine and vehicle solutions were blinded. Treatment was carried out every day during the 
morning hours between 9 am and 11 am. Mice were sacrificed on day 14 post grafting.
During autopsy primary tumors were scored based on their infiltration rate into surrounding tissues based on 
macroscopic appearance of the tumor. “Low infiltration” class means that primer tumor remained in the mam-
mary fat pads without any attachment to muscle tissues. In case the tumor mass attached to the muscle tissue but 
did not penetrate to the abdominal wall, it classified as a “medium infiltration” tumor. If the tumor grew into the 
muscle tissue and totally penetrated the abdominal wall, it was scored as a “high infiltration” tumor.
Both primary and metastatic tumor masses were removed from mice and were measured on analytical balance 
in preweighed Eppendorf tubes.
Human studies. We assessed the abundance of the bacterial DNA coding for lysine decarboxylase in human 
fecal DNA samples. The human fecal samples were collected from healthy women and breast cancer patients by 
collaborators at the National Cancer Institute (NCI), Kaiser Permanente Colorado (KPCO), and the Institute for 
Genome Sciences at the University of Maryland School of Medicine, and RTI International. The study protocol 
and all study materials were approved by the Institutional Review Boards at KPCO, NCI, and RTI International 
(IRB number 11CN235). The primary study results were published in18. All methods were performed in accord-
ance with the relevant guidelines and regulations.
We obtained informed consent from study participants.
Another cohort was used to assess LdcC protein in the feces of healthy volunteers and breast cancer patients. 
The collection and biobanking of feces was authorized by the Hungarian national authority (ETT). Patients and 
healthy volunteers meeting the following criteria were excluded from the study according to the corresponding 
national guideline for fecal transplantation68: (1) has previous history of breast cancer or had been operated due 
to neoplasia, (2) has a disease of unknown origin, (3) has chronic contagious disease, (4) had contagious diarrhea 
6 months prior to enrollment, (5) taken antibiotics in the 6 months prior to enrollment, (6) had chemotherapy, 
biological therapy or immunosuppressive therapy 6 months prior to enrollment, (7) used intravenous drugs 12 
months prior to enrollment, (8) had piercing, tattooing, acupuncture or other endangering behavior or action 12 
months prior to enrollment, (9) exposition to an allergen to which the enrolled individual had been sensitized to, 
(10) underwent colonoscopy 12 months prior to enrollment. First morning feces was sampled; samples were fro-
zen and deposited in the biobank two hours after defecation. Samples were stored at −70 °C until subsequent use.
Database screening. The kmplot.com database69 was used to study the link between gene expression levels and 
breast cancer survival in humans. The association of known mutations with breast cancer was retrieved from www.
intogen.org/. The sequence of the CadA and LdcC ORFs were retrieved from the KEGG (www.genome.jp/kegg/) 
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database. We assessed the NCBI GEO Profiles with the term “LDC and breast cancer” and the GENT database 
with the keywords “TAAR1”, “TAAR8” and “TAAR9”.
statistical analysis. We used two tailed Student’s t-test for the comparison of two groups unless stated 
otherwise. Fold data for human fecal DNA assessment were log2 transformed to achieve normal distribution. 
For multiple comparisons one-way analysis of variance test (ANOVA) was used followed by Tukey’s honestly 
significance (HSD) post-hoc test. Data is presented as average ± SEM unless stated otherwise. Texas Red-X 
Phalloidin-labelled fluorescent pictures were analyzed using Image J or Cell Profiler 2.0 followed by Advanced 
Cell Classifier 3.0. FACS results were analyzed using Flowing Software 2.0. Statistical analysis was done using 
Origin 8.6 software unless stated otherwise.
Data Availability
All primary data is accessible at https://figshare.com/s/b694cc9ab2f1d31ae9c7 or https://doi.org/10.6084/m9.
figshare.5657326.
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